



(11) **EP 3 146 051 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 72

(51) Int Cl.:
C12N 15/113 ^(2010.01) **A61K 31/7088** ^(2006.01)

(86) International application number:
PCT/US2015/031783

(48) Corrigendum issued on:
27.11.2019 Bulletin 2019/48

(87) International publication number:
WO 2015/179525 (26.11.2015 Gazette 2015/47)

(45) Date of publication and mention
of the grant of the patent:
04.09.2019 Bulletin 2019/36

(21) Application number: **15795373.8**

(22) Date of filing: **20.05.2015**

(54) **HUNTINGTON'S DISEASE THERAPEUTIC COMPOUNDS**

THERAPEUTISCHE VERBINDUNGEN FÜR HUNTINGTON-KRANKHEIT

COMPOSÉS THÉRAPEUTIQUES POUR LA MALADIE DE HUNTINGTON

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **20.05.2014 US 201462000895 P**

(43) Date of publication of application:
29.03.2017 Bulletin 2017/13

(73) Proprietor: **University of Iowa Research**
Foundation
Iowa City, IA 52242 (US)

(72) Inventors:
• **DAVIDSON, Beverly, L.**
Iowa City, Iowa 52242 (US)
• **MAS MONTEYS, Alejandro**
Iowa City, Iowa 52242 (US)

(74) Representative: **PATERIS Patentanwälte PartmbB**
Altheimer Eck 13
80331 München (DE)

(56) References cited:
WO-A1-2012/109667 WO-A1-2014/007858
WO-A2-2008/134646 WO-A2-2008/150897
US-A1- 2009 004 668 US-A1- 2009 130 751
US-A1- 2010 291 673 US-A1- 2013 281 372

- **J. L. MCBRIDE ET AL.: "Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, vol. 105, no. 15, 15 April 2008 (2008-04-15), pages 5868-5873, XP055424282, US ISSN: 0027-8424, DOI: 10.1073/pnas.0801775105**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).